Residency · Residency · Geriatrics

Frailty - Screening, Diagnosis, and Intervention

Introduction

Frailty is a clinical state of increased vulnerability to adverse health outcomes resulting from aging-associated decline in reserve and function across multiple physiologic systems. It represents a critical threshold beyond which the organism can no longer maintain homeostasis in the face of stressors that would be easily tolerated by a robust individual. The prevalence of frailty increases dramatically with age, affecting approximately 10 to 15 percent of community-dwelling adults aged 65 and older and rising to 25 to 50 percent of those aged 85 and above.

Frailty is conceptually distinct from both disability and comorbidity, though these three states frequently coexist. Disability refers to difficulty or dependence in carrying out activities essential to independent living; comorbidity denotes the concurrent presence of two or more diseases. Frailty, by contrast, describes the underlying biological vulnerability that predisposes to both. It is arguably the most important prognostic factor in geriatric medicine, independently predicting falls, hospitalization, surgical complications, disability, institutionalization, and death.

Conceptual Models of Frailty

Fried Phenotype Model (Physical Frailty)

The most widely used operational definition of frailty was developed by Linda Fried and colleagues from the Cardiovascular Health Study (CHS), published in 2001. This model defines frailty as a clinical syndrome based on five criteria: unintentional weight loss of more than 10 pounds or 5 percent or more of body weight in the prior year; self-reported exhaustion, assessed by specific items from the Center for Epidemiologic Studies Depression Scale (CES-D) occurring three or more days per week; weakness, defined as grip strength in the lowest 20th percentile adjusted for gender and BMI; slow walking speed, defined as the time to walk 15 feet in the lowest 20th percentile adjusted for gender and height; and low physical activity, defined as energy expenditure in the lowest 20th percentile in kilocalories per week.

The presence of three or more criteria defines frailty, one to two criteria defines pre-frailty, and zero criteria defines a robust state. Outcome data from the CHS demonstrated that frail individuals have a three-fold increased mortality risk and a two-fold increased hospitalization risk over three to seven years of follow-up. Pre-frailty is a dynamic and critically important state because approximately 23 percent of pre-frail individuals revert to robust status at 18 months, making intervention at this stage the most productive use of clinical resources. The principal limitation of the Fried phenotype model is its focus on the physical domain, excluding cognitive and psychosocial components that contribute meaningfully to vulnerability.

Rockwood Deficit Accumulation Model (Frailty Index)

Kenneth Rockwood and colleagues proposed an alternative conceptualization in which frailty is understood as the accumulation of health deficits across multiple domains. The Clinical Frailty Scale (CFS) is a practical 9-point visual scale ranging from very fit (1) to terminally ill (9), with a score of 5 or greater indicating mild frailty and a score of 7 or greater indicating severe frailty. The CFS was used extensively during the COVID-19 pandemic for triage decisions, as reflected in NICE rapid guidance documents.

The full Frailty Index (FI) calculates the ratio of deficits present to total deficits assessed, typically using 30 to 70 variables spanning medical diagnoses, functional limitations, cognitive impairment, and social factors. An FI of 0.25 or greater is considered frail, and a submaximal limit of approximately 0.67 has been identified, beyond which survival becomes incompatible with life. The continuous nature of the FI allows more granular risk stratification than the categorical Fried phenotype. Its principal advantage over the phenotype model lies in its ability to capture cognitive, mood, social, and functional deficits alongside physical ones.

Other Frailty Instruments

Several additional frailty assessment instruments are available for different clinical contexts. The FRAIL Scale developed by Morley includes five simple items covering fatigue, resistance (inability to climb one flight of stairs), ambulation (inability to walk one block), illness (five or more diseases), and loss of weight (greater than 5 percent), providing a quick bedside screen. The Edmonton Frail Scale encompasses 17 items across nine domains including cognition and social support. The Tilburg Frailty Indicator addresses physical, psychological, and social domains of frailty. The Electronic Frailty Index (eFI), validated by Clegg and colleagues in 2016 in UK primary care, enables automated calculation from electronic health records, offering a scalable approach to population-level frailty screening.

<image>A comparative diagram showing three major frailty assessment models side by side. On the left, show the Fried Phenotype model as a pentagon with five points labeled with each criterion (weight loss, exhaustion, weakness, slowness, low activity) with cut-off values. In the center, show the Rockwood Clinical Frailty Scale as a horizontal bar from 1-9 with color gradients (green 1-3, yellow 4-5, orange 6-7, red 8-9) and brief descriptors for each level. On the right, show the Frailty Index as a bar chart with deficit accumulation from 0 to 0.67, with thresholds marked. Below all three, include a comparison table showing sensitivity, specificity, time to administer, and domains captured for each model.</image>

Pathophysiology of Frailty

Biological Underpinnings

Frailty represents the failure of multiple integrated physiologic systems to maintain homeostasis under stress. The key pathways implicated in frailty pathogenesis include immune dysregulation, with elevated levels of IL-6, C-reactive protein, and TNF-alpha alongside impaired immune responses; endocrine dysfunction, characterized by low levels of testosterone, DHEA-S, IGF-1, and vitamin D coupled with cortisol dysregulation; sarcopenia, involving preferential loss of type II fast-twitch muscle fibers and mitochondrial dysfunction in skeletal muscle; neurological changes, including white matter disease, reduced brain volume, and impaired stress response; and metabolic derangements, including insulin resistance, impaired glucose homeostasis, and systemic energy dysregulation.

The Frailty Cycle

The frailty cycle describes a self-reinforcing downward spiral in which chronic undernutrition leads to loss of muscle mass, which reduces strength, which decreases walking speed, which reduces physical activity, which increases energy expenditure relative to intake, which perpetuates and worsens undernutrition. This vicious cycle accelerates functional decline unless deliberately interrupted at one or more entry points. The most effective points of intervention are nutrition (increasing protein and caloric intake to halt muscle wasting), exercise (breaking the cycle of inactivity and deconditioning), and treatment of the underlying drivers that initiated the cascade.

Biomarkers

No single validated biomarker for frailty has been established in clinical practice, reflecting the multisystem nature of the syndrome. Promising candidates include IL-6 and CRP as markers of inflammation, IGF-1 and DHEA-S as markers of anabolic hormone deficiency, the cortisol-to-DHEA ratio as an indicator of stress system dysregulation, GDF-15 as a marker of cellular stress, and cystatin C as a marker of renal function and overall physiological reserve. Composite biomarker panels and DNA methylation-based frailty clocks are under active investigation but are not yet ready for clinical deployment.

Frailty Screening in Clinical Practice

When to Screen

Frailty screening should be performed in all adults aged 70 and older at the initial clinical encounter and annually thereafter. It is also indicated for all adults presenting for surgical evaluation regardless of age, for those with significant chronic disease burden, at the time of hospital admission (where the CFS has been added to admission assessments in many institutions), and before chemotherapy decisions in geriatric oncology.

Recommended Screening Tools by Setting

The optimal screening tool varies by clinical context. In primary care, the FRAIL Scale (requiring one to two minutes) or a simple gait speed measurement provides efficient screening. In the hospital setting, the Clinical Frailty Scale can be completed visually in as little as 30 seconds. For preoperative assessment, the Modified Frailty Index-11 (mFI-11) and the Risk Analysis Index (RAI) are preferred. In research settings, the Fried Phenotype and full Frailty Index provide the most rigorous characterization. Gait speed alone, measured at less than 0.8 meters per second, has a sensitivity of 78 to 99 percent for detecting frailty and is arguably the simplest and most predictive single screening measure available.

Frailty and Clinical Decision-Making

Surgical Risk

Frailty is a stronger predictor of surgical outcomes than age or ASA class alone. An mFI-11 score of 0.27 or greater confers a two- to three-fold increased risk of 30-day mortality, postoperative complications, and hospital readmission. Data from the ACS-NSQIP database confirm that frailty predicts Clavien-Dindo grade IV and V surgical complications with robust discriminative ability. Preoperative comprehensive geriatric assessment combined with targeted optimization (prehabilitation) has been shown to reduce complications in frail surgical patients, making frailty screening before surgery not merely informative but actionable.

Cardiovascular Interventions

In the context of aortic valve replacement, frailty assessment influences the choice between transcatheter (TAVR) and surgical (SAVR) approaches. While frail patients may benefit from the less invasive TAVR approach, very frail patients may derive no benefit from either intervention, making frailty assessment essential for determining the ceiling of benefit. The FRAILTY-AVR trial demonstrated that a 5-meter gait speed below 0.83 meters per second independently predicted one-year mortality after aortic valve replacement regardless of approach.

A critical and frequently misunderstood point concerns anticoagulation in atrial fibrillation: frailty is expressly not a contraindication to anticoagulation. Indeed, frail patients with atrial fibrillation derive greater absolute benefit from anticoagulation than robust patients because their baseline stroke risk is higher. Withholding anticoagulation on the basis of frailty alone represents a failure of clinical reasoning.

Oncology

In geriatric oncology, the Geriatric-8 (G8) screening tool, scored out of 17, triggers a full CGA before chemotherapy decisions when the score falls to 14 or below. The Cancer and Aging Research Group (CARG) toxicity prediction score incorporates 11 variables to predict grade 3 to 5 chemotherapy toxicity, and frailty assessment predicts the inability to complete planned chemotherapy regimens. The ASCO guideline of 2018 recommends geriatric assessment for all adults aged 65 and older who are being considered for chemotherapy.

Critical Care

Frailty, defined as a CFS of 5 or greater, independently predicts ICU mortality, prolonged mechanical ventilation, and discharge to institutional care. Bagshaw and colleagues demonstrated in 2014 that a CFS of 5 or greater was associated with 1.81-fold adjusted odds of hospital mortality in ICU patients. Frailty assessment should ideally inform goals-of-care discussions before ICU admission rather than after deterioration has occurred.

<image>A clinical decision-making algorithm flowchart for incorporating frailty into treatment decisions. Start with "Older adult presenting for major intervention (surgery, chemotherapy, TAVR, etc.)." First box: "Screen for frailty (gait speed, CFS, or FRAIL scale)." Branch into three paths: "Robust (not frail)" leading to "Standard treatment approach with standard risk assessment"; "Pre-frail" leading to "Consider prehabilitation, CGA, optimize modifiable factors, then reassess"; "Frail" leading to "Full CGA, goals-of-care discussion, weigh treatment benefit vs. burden, consider modified/alternative approaches." Each endpoint should include specific examples of modified approaches for surgery, chemotherapy, and cardiac procedures. Include a side box noting "Frailty is NOT a reason to withhold treatment — it is a reason to individualize treatment."</image>

Interventions for Frailty

Exercise — The Most Evidence-Supported Intervention

Multicomponent exercise programs are the cornerstone of frailty intervention and represent the most effective single strategy for reversing or stabilizing frailty. Programs should incorporate resistance training, aerobic exercise, balance training, and flexibility work. The LIFE trial, published by Pahor and colleagues in 2014, demonstrated that a structured moderate-intensity physical activity program reduced mobility disability by 18 percent in sedentary adults aged 70 to 89 compared to a health education control.

Resistance training should be prescribed at a frequency of two to three sessions per week, at an intensity of 60 to 80 percent of one-repetition maximum, with progressive overload to ensure continued adaptation. This approach improves strength, gait speed, and chair stand performance. The Vivifrail program offers an individualized multicomponent exercise prescription based on frailty status and has been shown to improve SPPB scores by 1.4 points and gait speed by 0.11 meters per second, both exceeding minimum clinically important differences (0.05 to 0.1 m/s for gait speed; 0.5 to 1.0 points for SPPB). Tai chi, with its emphasis on balance, coordination, and weight shifting, reduces falls by 20 to 40 percent and is particularly beneficial for pre-frail individuals.

Nutritional Interventions

Protein intake in frail elderly patients should target 1.2 to 1.5 grams per kilogram per day, as recommended by the PROT-AGE study group. This represents a significant increase over the 0.8 g/kg/day recommended dietary allowance, which is insufficient to prevent muscle loss in aging. Protein should be distributed evenly across meals at 25 to 30 grams per meal to optimize muscle protein synthesis, as the anabolic response to protein feeding is blunted in elderly individuals (anabolic resistance) and requires a higher per-meal leucine threshold to trigger the mTOR signaling pathway. Leucine supplementation of 2.5 to 3 grams per meal may enhance this anabolic signaling.

Vitamin D should be supplemented if 25-hydroxyvitamin D levels fall below 30 ng/mL, at a dose of 800 to 2000 IU daily. Meta-analyses demonstrate that vitamin D combined with exercise is more effective than either alone. Oral nutritional supplements providing 400 kilocalories and 30 grams of protein per day have been shown to improve body weight and reduce mortality in malnourished hospitalized elderly. Overall caloric goals of 25 to 30 kcal/kg/day should be targeted to prevent further weight loss. Adherence to a Mediterranean diet has been associated with reduced frailty incidence, with a hazard ratio of 0.44 in the highest adherence quartile.

Pharmacological Interventions

No FDA-approved pharmacotherapy for frailty exists. Deprescribing, the systematic discontinuation of inappropriate medications, is itself a frailty intervention, as each unnecessary medication increases frailty risk through side effects, drug interactions, and physiological burden. Testosterone supplementation produces modest improvements in lean mass and strength in hypogonadal frail men, but the Testosterone Trials (TTrials) showed no benefit in physical function, and cardiovascular concerns have limited its use. Growth hormone and IGF-1 increase lean mass but not function and carry risks of diabetogenesis, edema, and carpal tunnel syndrome; they are not recommended. Myostatin inhibitors such as bimagrumab have shown Phase II data with increased lean mass, but functional benefits remain uncertain. ACE inhibitors have observational data suggesting protective effects on muscle function, but the LACE randomized controlled trial showed no benefit. GLP-1 receptor agonists should be used with caution in frail elderly due to concern about exacerbating sarcopenia through weight loss.

Multidomain Interventions

The combination of exercise, nutritional optimization, cognitive stimulation, and deprescribing yields the most robust outcomes. The SPRINT-T trial demonstrated that a multicomponent intervention combining physical activity, nutritional counseling, and technology-based monitoring reduced mobility disability in pre-frail and frail elderly participants. Hospital-based programs including ACE units, the Hospital Elder Life Program (HELP), and early mobilization protocols address frailty in the acute care setting.

Frailty Transitions and Trajectories

Frailty is a dynamic state, and transitions between frailty categories are common. Gill and colleagues demonstrated in 2006 that 58 percent of community-dwelling elderly transitioned between frailty states over 18 months of follow-up. Transitions from pre-frailty back to robust status are the most achievable, while transitions from established frailty to robust status are rare, occurring in fewer than 5 percent of cases. This dynamic pattern reinforces the critical importance of intervening at the pre-frailty stage, where the likelihood of benefit is highest. Acute illness can precipitate a rapid transition to frailty, a concept that aligns with the "post-hospital syndrome" described by Krumholz, in which hospitalization itself creates a period of generalized vulnerability extending well beyond the index diagnosis.

Key Clinical Pearls

• Frailty is the single strongest predictor of adverse outcomes in older adults undergoing surgery, chemotherapy, or critical care — screen before making treatment decisions
• Gait speed <0.8 m/s is the quickest single-measure frailty screen and predicts mortality as well as complex models
• Pre-frailty is the optimal intervention window — 23% of pre-frail individuals can revert to robust with exercise and nutritional optimization
• Frailty is NOT a contraindication to treatment — it is an indication for treatment individualization and shared decision-making
• Exercise (multicomponent: resistance + aerobic + balance) is the most effective single intervention for frailty — prescribe it like medication
• Protein intake of 1.2-1.5 g/kg/day distributed across meals is essential for frail elderly — most are severely protein-deficient

References

1. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-M156.
2. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489-495.
3. Pahor M, Guralnik JM, Ambrosius WT, et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA. 2014;311(23):2387-2396.
4. Clegg A, Bates C, Young J, et al. Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing. 2016;45(3):353-360.
5. Dent E, Morley JE, Cruz-Jentoft AJ, et al. Physical frailty: ICFSR international clinical practice guidelines for identification and management. J Nutr Health Aging. 2019;23(9):771-787.

Read this lecture as Markdown